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In this issue of Cancer Cell, She et al. show that in cancer cells a protein called 4E-BP1 is a key integrator of
protein synthesis downstream of the ERK and AKT signaling pathways, providing an intriguing rationale for
why their simultaneous targeting could enhance therapeutic efficacy.Intracellular signaling pathways mediate
cell responses to extracellular signals. In
cancer, acquired somatic mutations in
components of these pathways create
activated oncogenes that drive constitu-
tive mitogen-independent signaling,
upon which the cancer cells come toFigure 1. The RAF/ERK and PI3K/AKP Pathways Interact to Regulate
Protein Synthesis
The RAF/ERK and PI3K/AKT pathways can be activated by mutations in key
oncogenes or tumor suppressors (orange). These pathways both stimulate 4E-
BP1 phosphorylation, which initiates protein synthesis by releasing eIF4E.
Thus, inhibition of both pathways may be needed to block protein synthesis
and induce cancer cell death.depend for proliferation and
survival. This phenomenon
of ‘‘oncogene addiction’’
(Weinstein and Joe, 2008) is
believed to underlie the
selective activity of targeted
therapies against cancer
cells over normal cells.
However, despite the impli-
cations of its name, onco-
gene addiction is rarely
absolute because aberrant
signaling from several path-
ways drives cancer cell
proliferation and survival
in vivo. Thus, effective
therapy requires simulta-
neous targeting of more
than one oncogene-driven
pathway. To this end, the
possible benefits of concur-
rent inhibition of the RAF/
ERK and PI3K/AKT path-
ways appears attractive
because they are down-
stream of oncogenic RAS or
are often jointly activated by
somatic mutations in genes
such as BRAF and PIK3CA
(Figure 1).
These pathways can be
inhibited separately, but in
this issue of Cancer Cell,
She et al. elegantly reveal
that it may be possible to
target both simultaneously
through a common down-stream effector (She et al., 2010). Their
starting point was to identify cancers cells
that require both pathways for survival.
Critically, they then demonstrated that
the pathways converge on a repressor of
protein synthesis called 4E-BP1. Obvi-
ously, new protein synthesis is essentialCancer Cfor tumor growth and for many of the
essential proteins—such as the cell cycle
regulator cyclin D1, the antiapoptotic
protein bcl2, and the proangiogenic
growth factor VEGF—the rate-limiting
step in synthesis is binding of the eIF4F
initiation complex to the 50 cap of theirell 18, July 1messenger RNAs, which
initiates ribosome assembly
and protein translation (Graff
and Zimmer, 2003). 4E-BP1
inhibits protein synthesis by
binding to the eIF4E initiation
complex and preventing it
from binding to the 50 cap,
but this inhibition is over-
come by 4E-BP1 phosphor-
ylation, which releases the
eIF4E complex (Richter and
Sonenberg, 2005). By using
small molecule inhibitors,
RNA interference, and
genetic knockout cells, She
et al. show that RAF/ERK
and PI3K/AKT signaling
must both be inhibited to
stimulate 4E-BP1 dephos-
phorylation, demonstrating
that they independently con-
tribute to protein synthesis in
cancer cells.
The regulation of protein
synthesis is immensely
complex, but a key inte-
grator of this process is
a protein kinase called mam-
malian target of rapamycin
(mTOR), which directly
phosphorylates 4E-BP1
(Figure 1). Notably, ERK and
an ERK downstream kinase
called p90RSK phosphorylate
and inhibit the TSC1/2
complex, allowing the small3, 2010 ª2010 Elsevier Inc. 5
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PreviewsG protein RHEB to activate mTOR (Tee
and Blenis, 2005). AKT also phosphory-
lates and inhibits TSC1/2 and additionally
inhibits the action of the mTOR inhibitor
PRAS40 (Vander Haar et al., 2007).
Thus, She et al. conclude that both path-
ways stimulate protein synthesis through
mTOR and go on to demonstrate that
MEK and AKT inhibitors synergize to
suppress the growth of colon cancer
tumors that carry RAS and PIK3CA muta-
tions, that these inhibitors cooperate to
block in vivo phosphorylation of 4E-BP1,
and that constitutively active 4E-BP1
slows tumor growth. These results rein-
force the importance of protein synthesis
for tumor growth and robustly support
the identification of 4E-BP1 as a critical
integrator of RAF/ERK and PI3K/AKT
signaling.
A key implication of these data is that
4E-BP1 is a potential therapeutic target
in both pathways. Although 4E-BP1 itself
may not be a tractable target, the mTOR
inhibitor AZD8055 is relatively effective
at blocking 4E-BP1 phosphorylation
(Chresta et al., 2010), suggesting that
mTOR drugs could suppress protein
synthesis downstream of ERK and AKT
pathway oncogenes. This important
node could thus be used to inhibit both
pathways simultaneously or to enhance
the effects of upstream drugs. Dual
PI3K/mTOR inhibitors such as BEZ235,
which already achieve some degree of
combined blockade, may be the most
effective to combine with ERK pathway
drugs in the class of tumor studied by
She et al. Note, however, that this combi-6 Cancer Cell 18, July 13, 2010 ª2010 Elsevination may not be effective in all tumors,
because the antiproliferative activity of
BEZ235 is independent of BRAF/PTEN
mutation in some cells (Brachmann
et al., 2009).
The findings of She et al. highlight the
importance of understanding the biology
of signaling, the underlying genetics of a
specific tumor, and the mechanisms
of action of targeted therapies, in order
to best deploy combinations of inhibitors
or dual kinase inhibitors in patients. Our
naive view of cancer signaling is maturing
into an understanding that the pathways
are not linear, but embedded in highly
versatile networks that can adapt to
inhibition at single points. Thus, to
achieve effective therapy, the networks
must be targeted at several critical nodes
and here we note that genome-wide
sequencing shows that cancer cells
acquire 20,000–30,000 somatic muta-
tions (McCarthy, 2010), warning us that
our understanding of signaling
complexity, although quite advanced,
may still be in its infancy. Studies such
as the one presented by She et al. could
change treatment paradigms in cancer,
but they will surely need to be under-
pinned by a comprehensive snapshot of
the genetic aberrations of an individual
tumor to allow appropriate clinical deci-
sions to be made. As advances in technol-
ogies to provide this information move
ahead at breathtaking pace, the need for
improved understanding of the underlying
biology as provided by She et al.
becomes all the more important. Their
data show that some cancer cells caner Inc.tolerate loss of signaling from either
pathway, a process of ‘‘oncogene addic-
tion switching’’ that could represent
a major hurdle in cancer treatment.
However, this study also provides hope
that we may be able to overcome this
problem. In identifying an important inte-
grator of the RAF/ERK and PI3K/AKT,
they provide a potentially new target,
a possible biomarker for measuring
responses to treatment, and a firm ratio-
nale for why it is important to inhibit both
pathways in this class of tumor.REFERENCES
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